|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.960 USD | -0.67% |
|
-6.74% | +22.15% |
| 06-02 | Karyopharm Therapeutics Inc. - Special Call | |
| 06-02 | Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis | MT |
| Market Cap | 204M 179M 165M 154M 290M 19.32B 292M 1.96B 764M 9.5B 767M 751M 33B | P/E 2026 * |
-2.17x | P/E 2027 * | -2.91x |
|---|---|---|---|---|---|
| Enterprise Value | 457M 400M 370M 345M 648M 43.23B 653M 4.39B 1.71B 21.25B 1.72B 1.68B 73.83B | EV / Sales 2026 * |
3.33x | EV / Sales 2027 * | 1.32x |
| Free-Float |
95.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Karyopharm Therapeutics Inc.
| 1 day | -0.67% | ||
| 1 week | -6.74% | ||
| Current month | -1.21% | ||
| 1 month | +10.17% | ||
| 3 months | +34.98% | ||
| 6 months | +23.66% | ||
| Current year | +22.15% |
| 1 week | 8.85 |  | 9.83 |
| 1 month | 8.22 | | 10.22 |
| Current year | 5 | | 10.99 |
| 1 year | 3.65 | | 10.99 |
| 3 years | 3.51 | | 30.3 |
| 5 years | 3.51 | | 220.95 |
| 10 years | 3.51 | | 444.15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 58 | 2021-05-02 |
Lori Macomber
DFI | Director of Finance/CFO | 55 | 2025-01-02 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barry Greene
BRD | Director/Board Member | 62 | 2012-12-31 |
| Director/Board Member | 61 | 2013-03-31 | |
Garen Bohlin
BRD | Director/Board Member | 78 | 2013-10-02 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-20 | Free | Director | 15,508 | 0.0688% | ||
| 05-20 | Free | Director | 15,508 | 0.0688% | ||
| 05-20 | Free | Director | 15,508 | 0.0688% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67% | -6.74% | +107.62% | -70.48% | 204M | |
| +0.21% | -0.77% | +19.20% | -21.75% | 62.05B | |
| -0.84% | -9.93% | +57.21% | +194.41% | 54.52B | |
| -5.75% | +29.50% | +29.50% | +29.50% | 41.55B | |
| -2.96% | +4.99% | -53.01% | -60.20% | 39.06B | |
| +1.22% | +0.04% | +59.29% | -32.39% | 29.02B | |
| -7.06% | +14.71% | +132.96% | -50.37% | 25.38B | |
| +5.31% | +1.33% | +53.64% | +66.92% | 19.62B | |
| -1.05% | -1.44% | -3.02% | +139.59% | 16.89B | |
| +1.04% | +2.25% | +60.69% | +111.01% | 15.89B | |
| Average | -1.05% | +1.92% | +46.41% | +30.62% | 30.42B | |
| Weighted average by Cap. | -1.40% | +0.90% | +34.68% | +37.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 137M 120M 111M 104M 194M 12.97B 196M 1.32B 513M 6.38B 515M 504M 22.15B | 155M 136M 126M 117M 220M 14.68B 222M 1.49B 580M 7.22B 583M 570M 25.07B |
| Net income | -121M -106M -97.82M -91.3M -171M -11.44B -173M -1.16B -452M -5.62B -454M -445M -19.53B | -135M -118M -109M -101M -191M -12.71B -192M -1.29B -503M -6.25B -505M -494M -21.71B |
| Net Debt | 253M 221M 204M 191M 358M 23.91B 361M 2.43B 945M 11.75B 950M 929M 40.84B | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-22 | 8.990 $ | -0.33% | 226,551 |
| 26-06-18 | 9.020 $ | -4.04% | 492,124 |
| 26-06-17 | 9.400 $ | +3.30% | 283,580 |
| 26-06-16 | 9.100 $ | -5.60% | 322,103 |
| 26-06-15 | 9.640 $ | +1.47% | 172,462 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KPTI Stock
Select your edition
All financial news and data tailored to specific country editions
